Ottawa gave more details on Friday on the two vaccines Health Canada just approved for COVID-19.
Federal officials say they will be given in two doses and they can be kept at refrigerated temperatures for at least six months.
The AstraZeneca vaccine is developed in partnership with Oxford University, and the Serum Institute of India’s version of the same shot will be the first Viral-Vector based vaccines green-lit for use against the coronavirus in Canada.
These types of vaccines use non-replicating viral vectors or pieces, that are unable to make new viral particles and only produce the vaccine antigen.
Authorized for use in people over 18 years of age, AstraZeneca’s vaccine will be administered as a two-dose regimen and can be kept at refrigerated temperatures for at least six months.
Health Canada said AstraZeneca’s greater flexibility in dose-storage will facilitate distribution across the country.
Canada has seen a concerning rise in measles cases in the first months of 2024.
By the third week of March, the country had already recorded more than three times the number of cases as all of last year. Canada had just 12 cases of measles in 2023, up from three in 2022.
function buildUserSwitchAccountsForm()
var form = document.getElementById(‘user-local-logout-form-switch-accounts’);
if (form) return;
// build form with javascript since having a form element here breaks the payment modal.
var switchForm = document.createElement(‘form’);
switchForm.setAttribute(‘id’,’user-local-logout-form-switch-accounts’);
switchForm.setAttribute(‘method’,’post’);
switchForm.setAttribute(‘action’,’https://www.thestar.com/tncms/auth/logout/?return=https://www.thestar.com/users/login/?referer_url=https%3A%2F%2Fwww.thestar.com%2Fnews%2Fcanada%2Ftoronto-reports-2-more-measles-cases-use-our-tool-to-check-the-spread-in-canada%2Farticle_20aa7df4-e88f-11ee-8fad-8f8368d7ff53.html’);
switchForm.setAttribute(‘style’,’display:none;’);
var refUrl = document.createElement(‘input’); //input element, text
refUrl.setAttribute(‘type’,’hidden’);
refUrl.setAttribute(‘name’,’referer_url’);
refUrl.setAttribute(‘value’,’https://www.thestar.com/news/canada/toronto-reports-2-more-measles-cases-use-our-tool-to-check-the-spread-in-canada/article_20aa7df4-e88f-11ee-8fad-8f8368d7ff53.html’);
var submit = document.createElement(‘input’);
submit.setAttribute(‘type’,’submit’);
submit.setAttribute(‘name’,’logout’);
submit.setAttribute(‘value’,’Logout’);
function handleUserSwitchAccounts()
window.sessionStorage.removeItem(‘bd-viafoura-oidc’); // clear viafoura JWT token
// logout user before sending them to login page via return url
document.getElementById(‘user-local-logout-form-switch-accounts’).submit();
return false;
As we recognize Cancer Awareness Month, we stand together to raise awareness, support those affected, advocate for prevention, early detection, and continued research towards a cure. Cancer is the leading cause of death for Métis women and the second leading cause of death for Métis men. The Otipemisiwak Métis Government of the Métis Nation Within Alberta is working hard to ensure that available supports for Métis Citizens battling cancer are culturally appropriate, comprehensive, and accessible by Métis Albertans at all stages of their cancer journey.
Receiving a cancer diagnosis, whether for yourself or a loved one, can feel overwhelming, leaving you unsure of where to turn for support. In June, our government will be launching the Cancer Supports and Navigation Program which will further support Métis Albertans and their families experiencing cancer by connecting them to OMG-specific cancer resources, external resources, and providing navigation support through the health care system. This program will also include Métis-specific peer support groups for those affected by cancer.
With funding from the Canadian Partnership Against Cancer (CPAC) we have also developed the Métis Cancer Care Course to ensure that Métis Albertans have access to culturally safe and appropriate cancer services. This course is available to cancer care professionals across the country and provides an overview of who Métis people are, our culture, our approaches to health and wellbeing, our experiences with cancer care, and our cancer journey.
Together, we can make a difference in the fight against cancer and ensure equitable access to culturally safe and appropriate care for all Métis Albertans. Please click on the links below to learn more about the supports available for Métis Albertans, including our Compassionate Care: Cancer Transportation program.
You may have heard of Ozempic, the “miracle drug” for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes? In Canada, diabetes affects approximately 10 per cent of the general population. Of those cases, 90 per cent have Type 2 diabetes.
This metabolic disorder is characterized by persistent high blood sugar levels, which can be accompanied by secondary health challenges, including a higher risk of stroke and kidney disease.
Locks and keys
In Type 2 diabetes, the body struggles to maintain blood sugar levels in an acceptable range. Every cell in the body needs sugar as an energy source, but too much sugar can be toxic to cells. This equilibrium needs to be tightly controlled and is regulated by a lock and key system.
In the body’s attempt to manage blood sugar levels and ensure that cells receive the right amount of energy, the pancreatic hormone, insulin, functions like a key. Cells cover themselves with locks that respond perfectly to insulin keys to facilitate the entry of sugar into cells.
Unfortunately, this lock and key system doesn’t always perform as expected. The body can encounter difficulties producing an adequate number of insulin keys, and/or the locks can become stubborn and unresponsive to insulin.
All forms of diabetes share the challenge of high blood sugar levels; however, diabetes is not a singular condition; it exists as a spectrum. Although diabetes is broadly categorized into two main types, Type 1 and Type 2, each presents a diversity of subtypes, especially Type 2 diabetes.
To better serve people living with Type 2 diabetes, and to move away from a “one size fits all” approach, it is beneficial to understand which subtype of Type 2 diabetes a person lives with. When someone needs a blood transfusion, the medical team needs to know the patient’s blood type. It should be the same for diabetes so a tailored and effective game plan can be implemented.
This article explores four unique subtypes of Type 2 diabetes, shedding light on their causes, complications and some of their specific treatment avenues.
Severe insulin-deficient diabetes: We’re missing keys!
Insulin is produced by beta cells, which are found in the pancreas. In the severe insulin-deficient diabetes (SIDD) subtype, the key factories — the beta cells — are on strike. Ultimately, there are fewer keys in the body to unlock the cells and allow entry of sugar from the blood.
SIDD primarily affects younger, leaner individuals, and unfortunately, increases the risk of eye disease and blindness, among other complications. Why the beta cells go on strike remains largely unknown, but since there is an insulin deficiency, treatment often involves insulin injections.
Severe insulin-resistant diabetes: But it’s always locked!
In the severe insulin-resistant diabetes (SIRD) subtype, the locks are overstimulated and start ignoring the keys. As a result, the beta cells produce even more keys to compensate. This can be measured as high levels of insulin in the blood, also known as hyperinsulinemia.
Mild obesity-related diabetes: The locks are sticky!
Mild obesity-related (MOD) diabetes represents a nuanced aspect of Type 2 diabetes, often observed in individuals with higher body weight. Unlike more severe subtypes, MOD is characterized by a more measured response to insulin. The locks are “sticky,” so it is challenging for the key to click in place and open the lock. While MOD is connected to body weight, the comparatively less severe nature of MOD distinguishes it from other diabetes subtypes.
To minimize complications, treatment should include maintaining a healthy diet, managing body weight, and incorporating as much aerobic exercise as possible. This is where drugs like Ozempic can be prescribed to control the evolution of the disease, in part by managing body weight.
Mild age-related diabetes: I’m tired of controlling blood sugar!
Mild age-related diabetes (MARD) happens more often in older people and typically starts later in life. With time, the key factory is not as productive, and the locks become stubborn. People with MARD find it tricky to manage their blood sugar, but it usually doesn’t lead to severe complications.
While efforts have been made to classify diabetes subtypes, new subtypes are still being identified, making proper clinical assessment and treatment plans challenging.
In Canada, unique cases of Type 2 diabetes were identified in Indigenous children from Northern Manitoba and Northwestern Ontario by Dr. Heather Dean and colleagues in the 1980s and 90s. Despite initial skepticism from the scientific community, which typically associated Type 2 diabetes with adults rather than children, clinical teams persisted in identifying this as a distinct subtype of Type 2 diabetes, called childhood-onset Type 2 diabetes.
Acknowledging this distinct subtype of Type 2 diabetes in First Nations communities has led to the implementation of a community-based health action plan aimed at addressing the unique challenges faced by Indigenous Peoples. It is hoped that partnered research between communities and researchers will continue to help us understand childhood-onset Type 2 diabetes and how to effectively prevent and treat it.
A mosaic of conditions
Type 2 diabetes is not uniform; it’s a mosaic of conditions, each with its own characteristics. Since diabetes presents so uniquely in every patient, even categorizing into subtypes does not guarantee how the disease will evolve. However, understanding these subtypes is a good starting point to help doctors create personalized plans for people living with the condition.
While Indigenous communities, lower-income households and individuals living with obesity already face a higher risk of developing Type 2 diabetes than the general population, tailored solutions may offer hope for better management. This emphasizes the urgent need for more precise assessments of diabetes subtypes to help customize therapeutic strategies and management strategies. This will improve care for all patients, including those from vulnerable and understudied populations.